US2010136014A1PendingUtilityA1

GIPs, a Family of Polypeptides with Transcription Factor Activity that Interact with Goodpasture Antigen Binding Protein

63
Assignee: SAUS JUANPriority: Dec 7, 2001Filed: Sep 30, 2009Published: Jun 3, 2010
Est. expiryDec 7, 2021(expired)· nominal 20-yr term from priority
Inventors:Juan SausFrancisco Revert-Ros
A61P 35/00C07K 16/18A61P 37/06C07K 14/4702A61P 37/00A61K 38/00
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides isolated GPBP-interacting 90 and 130 kDa polypeptides, and portions thereof (GIP90/130 polypeptides), antibodies to the GIP90/130 polypeptides, and pharmaceutical compositions thereof. The present invention also provides isolated GIP90/130 nucleic acid sequences, expression vectors comprising the nucleic acid sequences, and host cells transfected with the expression vectors. The invention further provides methods for detecting the GIP90/130 polypeptides or nucleic acid sequences, methods for inhibiting interactions between GPBP and GIP90/130 polypeptides, between pol k76 and GIP90/130 polypeptides or aggregation of GIP90/130 polypeptides, and methods for treating patients with autoimmune disorders or cancer.

Claims

exact text as granted — not AI-modified
1 . An isolated polypeptide comprising at least 6 amino acids of the amino acid of SEQ ID NO:2. 
     
     
         2 . The isolated polypeptide of  claim 1  comprising the amino acid sequence of SEQ ID NO:2. 
     
     
         3 . The isolated polypeptide of  claim 1  comprising the amino acid sequence of SEQ ID NO:4. 
     
     
         4 . The isolated polypeptide of  claim 1  comprising the amino acid sequence of SEQ ID NO:6. 
     
     
         5 . The isolated polypeptide of  claim 1  comprising the amino acid sequence of SEQ ID NO:8. 
     
     
         6 . The isolated polypeptide of  claim 1  comprising the amino acid sequence of SEQ ID NO:10. 
     
     
         7 . The isolated polypeptide of  claim 1  comprising the amino acid sequence of SEQ ID NO:12. 
     
     
         8 . The isolated polypeptide of  claim 1  comprising the amino acid sequence of SEQ ID NO:14. 
     
     
         9 . The isolated polypeptide of  claim 1  comprising the amino acid sequence of SEQ ID NO:16. 
     
     
         10 . The isolated polypeptide of  claim 1  comprising the amino acid sequence of SEQ ID NO:32. 
     
     
         11 . The isolated polypeptide of  claim 1  comprising the amino acid sequence of SEQ ID NO:36. 
     
     
         12 - 22 . (canceled) 
     
     
         23 . An isolated polypeptide selected from the group consisting of SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:34, and SEQ ID NO:38. 
     
     
         24 . An antibody directed against a polypeptide comprising an amino acid sequence of one or more of the amino acid sequences selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, and SEQ ID NO:38. 
     
     
         25 . An isolated nucleic acid sequence comprising a sequence that hybridizes under high stringency conditions to a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:17, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:31, and SEQ ID NO:35. 
     
     
         26 . A recombinant expression vector comprising the isolated nucleic acid sequence of  claims 25 . 
     
     
         27 . A recombinant host cell transfected with the recombinant expression vector of  claim 26 . 
     
     
         28 . A method for modifying interactions between GPBP and GIP 90/130 polypeptides and/or pol k76 and GIP 90/130 polypeptides, comprising contacting cells with an amount effective of one or more GIP90/130 polypeptide or an antibody directed against one or more GIP90/130 polypeptide to modify the interaction between GPBP and GIP 90/130 polypeptides and/or pol k76 and GIP 90/130 polypeptides. 
     
     
         29 . A method for modifying aggregation of GIP 90/130 polypeptides comprising contacting cells with an amount effective of one or more GIP90/130 polypeptide or an antibody directed against one or more GIP90/130 polypeptide to modify the aggregation of GIP 90/130 polypeptides. 
     
     
         30 . A pharmaceutical composition comprising:
 a) an isolated polypeptide according to  claim 1 ; and   b) a pharmaceutically acceptable carrier.   
     
     
         31 . A pharmaceutical composition comprising:
 a) an antibody according to  claim 24 ; and   b) a pharmaceutically acceptable carrier.   
     
     
         32 . A method for treating a patient with an autoimmune disorder, comprising modifying the expression or activity of one or more GIP90/130 polypeptides in the patient with the autoimmune disorder. 
     
     
         33 . A method for treating a patient with a tumor, comprising modifying the expression or activity of one or more GIP90/130 polypeptides in the patient with the tumor.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.